Massachusetts – October 30, 2025 – Today, S2N Health announced the launch of its first AI Agent for MedTech sales teams, marking a major milestone toward the company’s mission of transforming commercialization with data-enabled, AI-powered solutions that vastly improve sales productivity and efficiency and accelerate the impact of innovative medical technologies. The RepSignal® Agent for MedTech Sales, now listed on Salesforce’s AgentExchange marketplace, positions S2N as one of the first MedTech-focused Salesforce partners to bring purpose-built, AI-powered intelligence natively into the Salesforce ecosystem, leveraging the Agentforce trust layer and fully embedding in commercial workflows in CRM environments where commercial teams already work.

The RepSignal® Agent will deliver real-time, customer-specific insights for pre-call readiness, account strategy, territory planning and more, tapping into S2N Health’s leading, multi-sourced healthcare data platform to deliver critical, actionable intelligence to the field that saves time, increases sales effectiveness, and automates workflows. Coupled with the RepSignal application that natively embeds deep IDN, Facility and HCP insights into the Salesforce CRM, the RepSignal Agent extends S2N Heath’s suite of fully integrated, end-to-end intelligence solutions for MedTech, enabling efficient execution of commercial strategy across commercial organizations.

“AI will redefine how medical technologies reach the market and the patients who need them, empowering field personnel to engage their customers with precision and confidence, and reducing non-productive time with smart, AI-driven automation,” said Amy Siegel, Co-Founder and CEO of S2N Health. “The launch of the RepSignal Agent is just the beginning—we aim to truly bend the cost curve of MedTech commercialization and are working with some of the biggest companies in the space to make this future a reality.”

S2N Health will be continuing to develop and deploy agents that address major pain points in commercialization, in MedTech and adjacent verticals, as the company in parallel expands its data assets, analytics layer, and integration features over the coming months.